What Ozempic is doing to women's hormones and why your doctor may not mention it

It’s a scenario that plays out constantly in Reddit’s r/Menopause community: A woman loses 25 pounds on Ozempic. She’s done everything right. She expected to feel better.

Instead, she felt worse. Her hot flashes intensified. She was waking up at 2 a.m. and couldn’t fall back asleep. Her mood was unpredictable in ways it had never been before. She asked her doctor if the medication was causing it. He told her it was probably just the adjustment period.

It wasn’t the medication. It was her hormones. And no one had warned her that losing weight that quickly could make that happen.

Many women on the forum describe losing weight on GLP-1s only to find themselves asking: Is this my GLP-1, or is this menopause? Often, it’s both — and the interaction between the two is something most prescribers aren’t trained to flag.

Below, Ivim Health’s Chief Medical Officer, Dr. Jessica Duncan, examines how rapid weight loss from GLP-1 medications may intersect with hormonal changes during perimenopause and menopause.

What’s actually happening

Fat tissue produces estrogen. It does this through an enzyme called aromatase, which converts androgens into estrogen. Research published in the journal Menopause found that aromatase gene expression in adipose tissue is significantly higher in postmenopausal women than in premenopausal women, meaning the body upregulates this process as ovarian production declines. For women in perimenopause, fat-tissue estrogen production isn’t a backup system. It becomes the primary source.

Lose fat rapidly — and GLP-1s can drive significant fat loss, sometimes 20% or more of total body weight — and you reduce that source. In postmenopausal women, intentional weight loss has been shown to produce meaningful reductions in estradiol and increases in SHBG. Whether GLP-1 receptor agonists drive these changes through weight loss alone or via a direct hormonal mechanism remains an open question — current evidence is largely limited to PCOS populations.

“This is clinically real and routinely missed,” says Duncan, a board-certified obesity medicine physician and Chief Medical Officer at Ivim Health. “Most GLP-1 prescribers are focused on metabolic outcomes, which makes sense. But they’re not always thinking about what rapid fat loss means hormonally for a woman who’s already in perimenopause or close to it. Those are not two separate conversations — they’re the same conversation.”

The perimenopause collision

Women in their 40s and early 50s are already in hormonal flux when many of them start GLP-1 therapy. Estrogen and progesterone are declining naturally. The fat loss doesn’t cause that decline — but it can accelerate a shift that was already in motion.

The symptoms that follow are easy to misattribute. Hot flashes worsen. Sleep deteriorates. Mood becomes harder to manage. These look like medication side effects. They look like “just menopause.” They get waved off as normal, temporary, or both — sometimes all three.

Women in these communities describe it consistently. “Nobody warned me this could happen.” “My doctor said it was just the adjustment period.” “I lost the weight I wanted to lose, and I feel worse than before I started.”

That gap between what’s happening and what patients are being told is the problem.

Sleep disruption is one of the most underestimated symptoms — and one of the most consequential. A systematic review of 86 studies in Sleep Medicine Reviews found strong evidence that the perimenopausal decline in estrogen and progesterone directly drives early-morning awakenings, increased nighttime wakefulness, and reduced total sleep time. Poor sleep raises cortisol, disrupts hunger hormones, and can work against the very progress a patient is trying to make. When a woman on a GLP-1 starts waking at 2 a.m. and can’t get back to sleep, that’s not a medication side effect to wait out. It may be a hormonal signal worth investigating.

The same is true for fatigue that rest doesn’t fix, mood changes that feel out of character, hot flashes that intensify after starting treatment, and a notable drop in libido. None of these in isolation proves a hormonal cause. But the pattern matters.

Why your doctor may not connect the dots

GLP-1 medications were developed and studied primarily through a metabolic lens — blood sugar, weight, cardiovascular risk. The prescribers writing the most GLP-1 prescriptions right now are often primary care providers and telehealth platforms, not gynecologists or endocrinologists with deep expertise in hormonal health. That’s not a criticism. It’s a structural reality. And it’s why the burden often falls on the patient to ask.

The medications themselves interact with hormonal biology in ways that aren’t yet well understood. A 2025 review in Endocrinology found that endogenous sex hormones — estrogen in particular — modulate GLP-1 receptor expression in the hypothalamus, and that women experience both greater weight loss and higher rates of side effects than men on GLP-1 agonists. Biology isn’t sex-neutral, and the prescribing conversation often is.

“If I’m seeing a woman in her 40s starting a GLP-1, I want to know where she is hormonally before we begin,” Duncan says. “Is she having symptoms of hormonal decline? How is she sleeping? Has she noticed changes in her cycle? I want that baseline, because if we’re going to drive significant fat loss, I want to understand what that’s going to mean for her specifically — not just her weight, but how she’s going to feel.”

That standard — a hormonal baseline before starting, and monitoring as loss progresses — is not yet common practice.

What to ask at your next appointment

You don’t need an extensive workup before starting a GLP-1. But if you’re a woman in your late 30s through 50s, a few questions are worth raising: Has my hormonal health been factored into this plan? What should I watch for that might indicate a hormonal shift? If I start experiencing sleep disruption, worsening hot flashes, or mood changes, is that something worth investigating?

If labs feel appropriate, relevant markers include but aren’t limited to estradiol, FSH, and progesterone, ideally timed in relation to your cycle if you’re still menstruating. Thyroid function is worth ruling out if fatigue and mood changes are prominent.

The bigger picture

A January 2026 retrospective cohort study published in The Lancet, conducted at Mayo Clinic, followed 120 postmenopausal women on tirzepatide for at least 12 months. Women who received concurrent menopause hormone therapy lost 35% more total body weight than those on tirzepatide alone — 17% versus 14% at 15 months — along with improved cardiometabolic outcomes. It’s the first published study to evaluate hormone therapy as a modifier of GLP-1 efficacy, and it suggests that treating both systems together produces meaningfully better results than treating either one in isolation.

“Weight loss and hormonal health aren’t two separate things,” Duncan says. “They’re deeply connected. And for women especially, treating one without awareness of the other is incomplete medicine. You deserve more than aiming for a number on a scale — you deserve to actually feel good.”

The women on r/Menopause asking, “Is this the Ozempic or is this menopause?” deserve a real answer. For many of them, it’s both — and there’s more that can be done about it than they’ve been told.

This story was produced by Ivim Health and reviewed and distributed by Stacker.